Tsukuba Institute of Research
VC Fund
Ibaraki, Japan
Tsukuba Institute of Research (筑波総研) is an R&D center owned by housing and wood products group Sumitomo Forestry. The facility develops technologies to make more effective use of wood in a wide range of fields.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
- Fund size:
- $4.5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Tsukuba Institute of Research invests in
Stages Tsukuba Institute of Research invests in
Countries Tsukuba Institute of Research invests in
Round sizes
Round size
- Seed
- $953k–$1.8M
- Series A
- $2M–$7.1M
Investment Focus
Industry
- Medical 5 (50%)
- Manufacturing 5 (50%)
- Health Care 3 (30%)
- Biotechnology 3 (30%)
- Sales 2 (20%)
Stage
- Series A 4 (40%)
- Seed 3 (30%)
- Funding Round 1 (10%)
- Venture - Series Unknown 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3M / Series A / May 08, 2024 | ||
| LIGHTz delivers a technology transfer and information exchange platform leveraging AI. | $5.7M / Series A / Mar 26, 2024 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.4M / Series A / Oct 25, 2022 | ||
| Veneno Technologies develops drug candidates for pharmaceutical companies. The company provides services that include the treatment of neurological, cardiovascular, and metabolic diseases, cancer cell proliferation, metastasis, and immune cell regulation. | $1.8M / Seed / Jan 24, 2022 | ||
| Alchemedicine is a the world in drug discovery with unique technologies and ideas Innovating new drug candidates for diseases with high unmet medical needs. | $7.1M / Series A / Feb 16, 2021 | ||
| Mel-Frontier uses the properties of magnesium alloys to invent new medical equipment, as well as to produce and market them. Their efforts to promote compliance and conduct fair research are ongoing. Based on implementation provisions for technology transfer promotion measures, AIST had awarded them the designation of AIST start-ups, and they arenow enjoying several useful treatments. | $1.3M / Seed / Oct 16, 2020 | ||
| FullDepth is a company that creates marine drones to aid with underwater monitoring. The company's drones work in tandem with marine navigation technology, which monitors and captures aquatic life, communicates data to connected devices, and provides infiltration information that can be freely used with a cloud service, allowing customers towitness and study marine life for educational and recreational purposes.FullDepth is a company that creates marine drones to aid with underwater monitoring. The company's drones work in tandem with marine navigation technology, which monitors and captures aquatic life, communicates data to connected devices, and provides infiltration information that can be freely used with a cloud service, allowing customers to witness and study marine life for educational and recreational purposes. | $48.2M / May 27, 2019 | ||
| O2 is a partner in the manufacturing industry that supports all activities that create value by making products and a proud mind. | $2.2M / Venture - Series Unknown / Jul 31, 2018 | ||
| Nanolux is a company which manufacture and sales of electronic devices such as night vision cameras and electronic device systems. | $2M / Series A / Jun 13, 2018 | ||
| AGREE is an application developer and operator for medical consultation. Its product is the medical consultation application, LEBER. It allows its users to consult with a doctor on their smartphone 24/7. It was founded in 2017 and is headquartered in Tsukuba, Ibaraki Prefecture, Japan. | $952.7K / Seed / Mar 22, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tsukuba Institute of Research invest in?
Tsukuba Institute of Research invests primarily in Medical, Manufacturing and Health Care startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tsukuba Institute of Research's check size?
Tsukuba Institute of Research typically joins rounds of $953k–$1.8M at Seed and $2M–$7.1M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tsukuba Institute of Research participates in.
When did Tsukuba Institute of Research last invest?
The most recent investment recorded for Tsukuba Institute of Research closed in May 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
